Researchers are exploring several strategies to optimize CHK1 inhibition in cancer therapy. One approach is the identification of biomarkers that predict response to CHK1 inhibitors, allowing for more personalized treatment plans. Another strategy is the combination of CHK1 inhibitors with other targeted therapies, immune checkpoint inhibitors, or PARP inhibitors, to enhance their therapeutic effect and overcome resistance mechanisms.
